相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
Brendan P. Hodkinson et al.
TRANSLATIONAL ONCOLOGY (2021)
MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies
Matthew Lee et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Beung-Chul Ahn et al.
CANCERS (2021)
Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia
Raffaele Frazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Progress on treatment of MET signaling pathway in non-small cell lung cancer
Xiaoqing Yu et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis
Tobias Raphael Overbeck et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
Shibo Wu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
MET-dependent solid tumours - molecular diagnosis and targeted therapy
Robin Guo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Targeting MET Dysregulation in Cancer
Gonzalo Recondo et al.
CANCER DISCOVERY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Application of FISH in the diagnosis of lung cancer
Lena Hieggelke et al.
PATHOLOGE (2020)
Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients
Chuanhao Tang et al.
CLINICA CHIMICA ACTA (2020)
Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib
Ye Wang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing
Jingwen Li et al.
LUNG CANCER (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
Gillianne Gy Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib
Xuanxuan Zheng et al.
LUNG CANCER (2019)
Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)
Fady M. Mikhail et al.
GENETICS IN MEDICINE (2019)
Detection of Solid Tumor Molecular Residual Disease(MRD) Using Circulating Tumor DNA (ctDNA)
Re-I Chin et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients
Satoru Kitazono et al.
CANCER SCIENCE (2019)
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi et al.
CLINICAL CANCER RESEARCH (2019)
How liquid biopsies can change clinical practice in oncology
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
Roberta Castiglione et al.
MODERN PATHOLOGY (2019)
Current and future perspectives of liquid biopsies in genomics-driven oncology
Ellen Heitzer et al.
NATURE REVIEWS GENETICS (2019)
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Bin-Chi Liao et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
N. Guibert et al.
ANNALS OF ONCOLOGY (2018)
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Sun Min Lim et al.
CANCER TREATMENT REVIEWS (2018)
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer
Lianghua Fang et al.
Oncotarget (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification
Eric Angevin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Genomic Analysis of Non-Small Cell Lung Cancer (NSCLC) Cases with Focal and Non-Focal MET Amplification
S. Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Capture-Based Targeted Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer
Xiaowei Mao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Current and Emerging Applications of Droplet Digital PCR in Oncology
Susana Olmedillas-Lopez et al.
MOLECULAR DIAGNOSIS & THERAPY (2017)
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis
Nieves Perdigones et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Droplet digital PCR measurement of HER2 in patients with gastric cancer
H. Kinugasa et al.
BRITISH JOURNAL OF CANCER (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
Hans-Ulrich Schildhaus et al.
CLINICAL CANCER RESEARCH (2015)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
Aya Tanaka et al.
LUNG CANCER (2012)
Lung Cancer: Epidemiology, Etiology, and Prevention
Charles S. Dela Cruz et al.
CLINICS IN CHEST MEDICINE (2011)
An overview of the c-MET signaling pathway
Shawna Leslie Organ et al.
Therapeutic Advances in Medical Oncology (2011)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
分享论文
